Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Transfusion ; 60(12): 2828-2833, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32989778

RESUMO

BACKGROUND: Arkansas is a rural state of 3 million people. It is ranked fifth for poverty nationally. The first case of coronavirus disease 2019 (COVID-19) in Arkansas occurred on 11 March 2020. Since then, approximately 8% of all Arkansans have tested positive. Given the resource limitations of Arkansas, COVID-19 convalescent plasma (CCP) was explored as a potentially lifesaving, therapeutic option. Therefore, the Arkansas Initiative for Convalescent Plasma was developed to ensure that every Arkansan has access to this therapy. STUDY DESIGN AND METHOD: This brief report describes the statewide collaborative response from hospitals, blood collectors, and the Arkansas Department of Health (ADH) to ensure that CCP was available in a resource-limited state. RESULTS: Early contact tracing by ADH identified individuals who had come into contact with "patient zero" in early March. Within the first week, 32 patients tested positive for COVID-19. The first set of CCP collections occurred on 9 April 2020. Donors had to be triaged carefully in the initial period, as many had recently resolved their symptoms. From our first collections, with appropriate resource and inventory management, we collected sufficient CCP to provide the requested number of units for every patient treated with CCP in Arkansas. CONCLUSIONS: The Arkansas Initiative, a statewide effort to ensure CCP for every patient in a resource-limited state, required careful coordination among key players. Collaboration and resource management was crucial to meet the demand of CCP products and potentially save lives.


Assuntos
COVID-19/terapia , Recursos em Saúde/provisão & distribuição , Acessibilidade aos Serviços de Saúde/organização & administração , Pandemias , Alocação de Recursos/organização & administração , SARS-CoV-2/imunologia , Anticorpos Antivirais/sangue , Arkansas/epidemiologia , Bancos de Sangue/economia , Bancos de Sangue/organização & administração , Doadores de Sangue/provisão & distribuição , COVID-19/sangue , COVID-19/economia , COVID-19/epidemiologia , Planejamento em Saúde Comunitária/economia , Planejamento em Saúde Comunitária/organização & administração , Busca de Comunicante , Convalescença , Recursos em Saúde/economia , Acessibilidade aos Serviços de Saúde/economia , Humanos , Imunização Passiva , Colaboração Intersetorial , Pobreza , Alocação de Recursos/economia , População Rural , Soroterapia para COVID-19
2.
J Ark Med Soc ; 111(12): 248-51, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25966598

RESUMO

Hepatitis C infection is the most common blood-borne infection in the United States with an estimated 2.7 million individuals suffering from chronic infection. Of those who are infected with Hepatitis C virus, 75-85% develop chronic infection. Without treatment for chronic infection, individuals can develop liver diseases, such as cirrhosis and hepatocellular carcinoma, during many years of asymptomatic infection. To examine the burden of Hepatitis C virus infection in the state, the Arkansas Department of Health created an epidemiologic profile based on data collected in 2013 from several data sources, including the department's Hepatitis C surveillance program. In order to make more Arkansans aware of their infection, the local health units in all 75 counties of the state recently began screening individuals at risk for the disease, including persons born during the years 1945-1965. Despite recent advances in treatment efficacy, identifying infected individuals and connecting patients to affordable HCV treatment and care remain priorities.


Assuntos
Hepatite C Crônica/epidemiologia , Adolescente , Adulto , Idoso , Antivirais/economia , Antivirais/uso terapêutico , Arkansas , Estudos Transversais , Custos de Medicamentos , Feminino , Anticorpos Anti-Hepatite C/sangue , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/transmissão , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Ribavirina/economia , Ribavirina/uso terapêutico , Fatores de Risco , Sofosbuvir , Uridina Monofosfato/análogos & derivados , Uridina Monofosfato/economia , Uridina Monofosfato/uso terapêutico , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA